{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":19,"n_cols":5,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[10,2,10,3],[11,2,11,3],[15,2,15,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910962265703321"]
[null,null,"Titolo",null,"COX-2 inhibitor research / / Maynard J. Howardell, editor"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Nova Science Publishers, c2006"]
[null,null,"ISBN",null,"1-61668-114-4"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (263 p.)"]
[null,null,"Disciplina",null,"615/.7"]
[null,null,"Soggetti",null,"Nonsteroidal anti-inflammatory agents"]
[{"$nulls":4},"Arthritis - Chemotherapy"]
[{"$nulls":4},"Anti-inflammatory agents"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Cyclooxygenase-2 inhibitor and gastric cancer / Yumin Li, Raaj K. Praseedom, and Andrew Butler et al. -- Prevention and chemoprevention of gastric cancer : dietary habits, Helicobacter pylori and COX-2 inhibitors / Gerardo Nardone and Alba Rocco -- Cyclooxygenases in cancer / Daniela Fodera ... et al. -- Nephrotoxicity of nonsteroidal anti-inflammatory drugs : focus on selective cyclooxygenase-2 (COX-2) inhibitors / Steven G. Coca and Mark A. Perazella -- Are COX-2 inhibitors active on intracellular oxidative processes? A study on in vitro and cellular models / Ange Mouithys-Mickalad et al. -- Theoretical mechanism studies on dual inhibition of human cyclooxygenase-2 and 5-lipoxygenase by diaryl-pyrrolizine derivatives / R. Pouplana, C. Perez, and J. Ruiz --"]
[{"$nulls":4},"NSAIDs in animal models of Alzheimer's disease / N.G. Giovannini, C. Scali, and A. Bellucci -- Relevance of COX-2 inhibitors in Alzheimer's disease / Amita Quadros, Laila Abdullah, and Nikunj Patel et al. -- COX.1-COX.2 simultaneous inhibitory mechanism in gastric injury and COX.2-COX.3 in small intestine injury / Laudanno Oscar -- Effects of COX-2 inhibitors on brain diseases / Takako Takemiya -- Cyclooxygenase-2 overexpression and the chemopreventive and therapeutic uses of cyclooxygenase inhibitors in lung cancer / Zhongxing Liao et al. -- Safety monitoring of celecoxib and rofecoxib in the New Zealand intensive medicines monitoring programme / David Coutler et al."]
[null,null,null,"Sommario/riassunto","COX-2 Inhibitors are newly developed drugs for inflammation that selectively block the COX-2 enzyme. Blocking this enzyme impedes the production of the chemical messengers (prostaglandins) that cause the "]
[{"$nulls":4},"pain and swelling of arthritis inflammation. Cox-2 inhibitors are a new class of nonsteroidal anti-inflammatory drugs (NSAIDS). Because they selectively block the Cox-2 enzyme and not the Cox-1 enzyme, these drugs are uniquely different from traditional NSAIDS. This new book explores new research in this field."]